Rise of E-Pharmacies in India: A Case Study on Growth, Operational Models, Regulatory Framework, and Future Prospects

Tooba Rizvi; Nandini Rupesh Vimal; Shailja Sahu; Aishwarya Srivastava; Ashwani Kumar

doi:10.5281/zenodo.20098700

Review Paper | Open Access
Volume 04 | Issue 05 | Article Id IJPS/260404911

Rise of E-Pharmacies in India: A Case Study on Growth, Operational Models, Regulatory Framework, and Future Prospects
Tooba Rizvi* Nandini Rupesh Vimal Shailja Sahu Aishwarya Srivastava Ashwani Kumar
Institute of Pharmaceutical Sciences and Research, Mahadev Campus, Lucknow-Kanpur Express Highway, Sohramau, Unnao, UP 209859

Abstract

India's pharmaceutical retail landscape has undergone a remarkable transformation over the past decade with the emergence and rapid expansion of e-pharmacies. Powered by rising internet connectivity, smartphone penetration, and a shift in consumer behaviour accelerated by the COVID-19 pandemic, online pharmacy platforms have become an increasingly significant channel for medicine delivery across urban, semi-urban, and aspirationally rural India. This paper presents a comprehensive case study of the rise of e-pharmacies in India — tracing their origins, examining the operational models adopted by major platforms, analysing the existing regulatory framework and its gaps, and evaluating the socioeconomic implications of this sector's growth. Key players including PharmEasy, 1mg, Netmeds, Apollo Pharmacy, and MedPlus are examined through the lens of their market strategies, acquisition histories, and service expansions. The study also identifies the critical unresolved challenges facing the sector, including prescription verification integrity, counterfeit medicine risks, cold chain limitations, data privacy concerns, and the displacement of traditional pharmacists. The paper concludes with a forward-looking perspective on how policy reform, technological integration, and a patient-centric regulatory approach can shape a responsible and inclusive e-pharmacy ecosystem in India.

Keywords

E-pharmacy, online pharmacy India, digital health, pharmaceutical regulation, telemedicine, drug delivery, NDPS, CDSCO, health-tech.

Introduction

The pharmaceutical industry in India is one of the most strategically important sectors of the national economy. With over 3,000 drug companies, approximately 10,500 manufacturing units, and a commanding presence in the global generics market, India supplies medicines to more than 200 countries. Domestically, however, the distribution of medicines to end consumers has long been characterised by a fragmented, largely informal network of retail chemist shops. While there are approximately 900,000 licensed pharmacies across the country, their geographical distribution is uneven, their operating practices vary widely, and access in rural and remote regions has historically been inadequate. This structural gap between pharmaceutical production capacity and patient-level access created a latent demand for more organised, convenient, and affordable medicine distribution — a gap that technology-driven e-pharmacy platforms have been working to fill since the early 2010s. The term 'e-pharmacy' or 'online pharmacy' refers to a digital platform through which consumers can browse, select, upload prescriptions, and order medicines for home delivery. Beyond medicines, these platforms have expanded into ancillary healthcare services including diagnostic test bookings, teleconsultation with doctors, health insurance, and wellness products. India's e-pharmacy sector began taking shape around 2013–2015 with early movers like 1mg, Netmeds, and PharmEasy. These platforms initially operated as medicine price comparison tools and health information portals before transitioning to full-scale delivery operations. Over the following decade, backed by a combination of venture capital, strategic acquisitions by major conglomerates, and a behaviour-shifting pandemic, the sector has grown into a multi-billion-dollar market with an estimated compound annual growth rate (CAGR) of 18–20% projected through 2028. [1] Despite this impressive growth narrative, the e-pharmacy sector in India continues to operate in a complex environment — one shaped by evolving consumer expectations, significant regulatory ambiguity, competitive pressures from traditional pharmacy networks, and genuine public health concerns about unregulated medicine dispensing. This paper presents a structured case study of this sector — examining its origins, growth trajectory, key players, operational models, regulatory framework, challenges, and future outlook.

BACKGROUND: THE TRADITIONAL PHARMACY SYSTEM AND ITS LIMITATIONS

To appreciate why e-pharmacies found such rapid acceptance in India, it is necessary to first understand the limitations of the traditional pharmacy infrastructure the country relied upon for decades. India's retail pharmacy network, though numerically large with nearly 900,000 licensed outlets, has historically suffered from multiple structural problems. First, geographical concentration has been severely skewed — the vast majority of pharmacies operate in urban centres, leaving rural India underserved. According to a 2019 study, approximately 65% of India's population residing in rural areas has access to only 30% of the country's pharmacy outlets. [2] This means a significant segment of the population must travel considerable distances, sometimes more than 20 kilometres, to purchase prescribed medicines. Second, medication continuity for patients with chronic diseases such as diabetes, hypertension, thyroid disorders, and cardiovascular conditions has been a persistent challenge. Patients in smaller towns often face stockouts of specific branded or even generic medicines, and there is no seamless mechanism for prescription refill reminders or record-keeping at the consumer level. Third, and perhaps most critically, the standard of pharmacy practice at the retail level has been inconsistent. The Pharmacy Act of 1948 mandates that a registered pharmacist must be present at every licensed pharmacy at all times. In practice, this requirement is widely violated — many retail pharmacies are operated by individuals with minimal pharmaceutical training, increasing the risk of incorrect dispensing, missed drug interaction warnings, and inappropriate advice to patients. [3] Fourth, pricing transparency has been a long-standing consumer grievance. While the government regulates the prices of medicines under the National List of Essential Medicines through the Drug Price Control Order (DPCO), non-essential drugs carry no such price ceiling, and retail markup practices are inconsistent and often opaque. These structural weaknesses created the conditions for a disruption. The emergence of e-pharmacies was not purely a technology story — it was, at its root, a response to genuine gaps in the traditional system.

THE GROWTH OF E-PHARMACIES IN INDIA: A PHASED ANALYSIS

Phase 1: Foundation and Early Operations (2013–2016)

The first wave of e-pharmacy activity in India was characterised by cautious entry and limited scope. Platforms like 1mg (initially launched as HealthkartPlus in 2013) and Netmeds (2015) began primarily as medicine information databases and price comparison tools. Consumers could check medicine compositions, compare prices across brands, and read about drug interactions — but the focus was on information rather than commerce. PharmEasy entered in 2014 with a more explicitly transactional model, partnering with local licensed pharmacies to fulfil delivery orders. This 'marketplace model' — where a platform aggregates inventory from multiple licensed pharmacy partners rather than holding its own stock — allowed PharmEasy to scale without significant capital investment in physical infrastructure. By 2016, operations were primarily concentrated in the four-metro cities of Mumbai, Delhi, Bengaluru, and Hyderabad, with a limited range of over-the-counter and prescription medicines available for delivery.

Phase 2: Venture Capital, Scaling, and Service Expansion (2017–2020)

The second phase was defined by aggressive fundraising and rapid geographic expansion. PharmEasy closed funding rounds totalling over USD 220 million between 2017 and 2020. 1mg raised over USD 165 million in similar timeframes. With this capital, platforms moved beyond metro cities into tier-2 and tier-3 markets, established their own distribution hubs and 'dark stores' (dedicated fulfilment centres not open to walk-in customers), and began investing in adjacent services. Diagnostics became a major growth area during this phase — platforms began offering home sample collection for blood tests and health screenings, creating a more complete healthcare service offering. Teleconsultation with doctors was introduced as an embedded feature, allowing patients to consult a physician and receive an e-prescription that could immediately be fulfilled on the same platform. This end-to-end integration of consultation, prescription, and medicine delivery represented a significant leap in the depth of service. During this phase, platforms also began building their own private label generic drug lines — offering in-house branded generics at significantly lower prices than originator brands. This moves deepened customer loyalty while improving platform margins. [4]

Phase 3: COVID-19 and the Inflection Point (2020–2022)

If there was a single event that transformed Indian e-pharmacies from a growing niche into a mainstream healthcare channel, it was the COVID-19 pandemic. When the national lockdown was imposed in March 2020, access to physical pharmacy stores became severely restricted. Millions of patients with chronic conditions — who depended on monthly medicine refills — were left without a clear mechanism to obtain their prescriptions. E-pharmacy platforms responded with extraordinary speed. Apps were downloaded in unprecedented numbers — industry estimates suggest a 200–300% spike in new user registrations across major platforms in April–May 2020. [5] Platforms worked with governments to obtain essential services exemptions, collaborated with local pharmacies and logistics partners for last-mile delivery, and in some cases offered priority delivery to senior citizens and immunocompromised patients. The pandemic also drove the normalisation of teleconsultation. The government's decision to allow teleconsultation under the Telemedicine Practice Guidelines issued in March 2020 created a legal framework for digital prescriptions, which in turn strengthened the e-pharmacy model. Patients who consulted doctors through video calls could receive digital prescriptions that platforms were equipped to accept. Post-lockdown, many first-time users retained the habit of online medicine purchase — a behavioural shift that delivered a durable new customer base to the sector.

Phase 4: Consolidation, Corporate Acquisition, and Maturation (2022–Present)

The fourth and current phase has been defined by corporate consolidation. India's largest conglomerates identified the e-pharmacy space as strategically critical to their respective healthcare ambitions. Tata Digital completed its acquisition of 1mg in 2021 for an estimated USD 325–350 million, integrating it into a broader health and wellness portfolio. Reliance Retail acquired Netmeds in 2020 for approximately INR 620 crore, folding it into its JioMart and health services ecosystem. Apollo Hospitals scaled its online pharmacy operations substantially under the Apollo Health and Lifestyle brand. These acquisitions brought brand credibility, larger capital reserves, and access to extensive distribution networks — but they also signalled a consolidation of market power. Smaller, independent e-pharmacy startups found it increasingly difficult to compete on price and reach against platforms backed by Tata and Reliance. IPO aspirations also came under scrutiny — PharmEasy's planned IPO was withdrawn in 2022 amid valuation corrections and profitability pressures, reflecting a broader recalibration of investor expectations in the health-tech space.

MAJOR PLAYERS: PROFILES AND MARKET PRESENCE

The following table provides an overview of the principal e-pharmacy platforms currently operating in India:

Table 1: Key E-Pharmacy Platforms in India (as of 2024–25)

Platform	Founded	Parent Company	Key Services	Revenue (FY23 approx.)
PharmEasy	2014	API Holdings	Medicines, diagnostics, teleconsult, wellness	~INR 6,200 Cr
1mg (Tata Health)	2013	Tata Digital	Medicines, labs, doctors, generics	~INR 1,967 Cr
Netmeds	2015	Reliance Retail	Medicines, OTC, health devices	~INR 1,200 Cr
Apollo Pharmacy	2020 (online)	Apollo Hospitals	Medicines, diagnostics, insurance	Part of Apollo Group
MedPlus Health	2006	MedPlus Ltd (listed)	Medicines, FMCG, diagnostics	~INR 4,200 Cr (all channels)

Beyond revenue and ownership, these platforms differ significantly in their operational approach. PharmEasy follows a hyperlocal marketplace model where orders are fulfilled through a network of partner pharmacies located close to the customer, enabling faster delivery. 1mg under Tata has pursued a more integrated approach — building its own inventory-holding fulfilment centres alongside a marketplace model, allowing better quality control and faster delivery for frequently ordered products. Apollo's hybrid model — leveraging its chain of physical pharmacies for both walk-in and online fulfilment — offers an advantage in prescription verification and cold chain reliability. [6]

E-PHARMACY vs. TRADITIONAL PHARMACY: A DETAILED COMPARISON

A structured comparison of the two models across key operational parameters reveals both the advantages that e-pharmacies bring and the areas where traditional pharmacies retain an edge:

Table 2: Operational Comparison — Traditional Pharmacy vs. E-Pharmacy

Parameter	Traditional Pharmacy	E-Pharmacy
Accessibility	Limited to nearby area and shop timings	24/7 availability; accessible from any location
Medicine Price	MRP, minimal discount	10–25% discount, cashback, loyalty rewards
Prescription Handling	Physical copy verified in person	Digital upload; verification quality varies
Product Range	Limited by shelf and storage space	Thousands of SKUs, generics, wellness products
Delivery Speed	Immediate (walk-in purchase)	Same-day to 5–7 days depending on region
Patient Counselling	Direct access to pharmacist	Limited; AI chatbots used on some platforms
Chronic Disease Supply	Patient must revisit monthly	Subscription and auto-refill models available
Record Keeping	Mostly paper-based, not shared	Digital prescription history maintained
Cold Chain Handling	Controlled in licensed premises	Inconsistent for remote delivery locations
Regulatory Status	Clear under Drugs & Cosmetics Act 1940	Grey zone; draft rules pending since 2018

As the comparison above demonstrates, e-pharmacies offer clear advantages in price, accessibility, and continuity of supply for chronic disease patients. However, gaps in patient counselling quality, prescription verification rigour, and cold chain reliability in remote areas represent areas where the traditional model continues to hold functional superiority. The long-term competitive equilibrium between the two models may well involve a hybrid approach — as Apollo and MedPlus have demonstrated — where a physical pharmacy network serves as the backbone for online operations.

OPERATIONAL MODELS IN THE INDIAN E-PHARMACY SECTOR

1. Marketplace Model

In this model, the e-pharmacy platform acts as an intermediary, connecting consumers with a network of registered partner pharmacies. The platform manages the digital interface — website and app — handles payments, and coordinates delivery logistics, but does not hold inventory itself. Orders are forwarded to the nearest partner pharmacy, which picks, packs, and dispatches the order. This model has low capital requirements and enables rapid geographic scalability. PharmEasy and Netmeds have historically operated variations of this model.

2. Inventory-Holding Model

In this model, the platform procures and stores medicines in its own warehouses or dark stores and fulfils orders directly. This allows greater control over product quality, storage conditions, and expiry management. It also enables more reliable cold chain handling for refrigerated medicines. The trade-off is higher capital expenditure and greater regulatory scrutiny, as the platform itself functions as a licensed drug distribution entity. 1mg under Tata operates significant inventory-holding capacity alongside its marketplace network.

3. Hybrid (Phygital) Model

The hybrid model integrates physical pharmacy infrastructure with digital operations. Platforms like Apollo Pharmacy and MedPlus use their nationwide networks of brick-and-mortar stores as fulfilment points for online orders. Customers can choose to have medicines delivered to their home or can opt for in-store pickup. This model is particularly effective for prescription verification (pharmacists at physical locations can authenticate prescriptions in person before dispatch) and for temperature-sensitive medicines. [7]

4. Subscription and Chronic Care Model

Several platforms have developed specialised subscription programmes targeting patients with chronic diseases. Consumers upload their prescription once and set up an automatic monthly refill. The platform sends reminders, processes the order on a defined schedule, and delivers medicines without the patient needing to re-initiate the transaction each time. This model dramatically improves medication adherence for chronic conditions — a significant public health benefit — while delivering predictable recurring revenue for the platform.

REGULATORY LANDSCAPE

Current Legal Framework

The Indian e-pharmacy sector currently operates within a regulatory framework that was not designed for it. The Drugs and Cosmetics Act of 1940 — the primary legislation governing the manufacture, distribution, and sale of drugs in India — was conceived exclusively for brick-and-mortar operations. It does not include provisions for digital platforms, electronic prescriptions, or online transactions involving prescription drugs. Similarly, the Pharmacy Act of 1948, which governs pharmacy practice and the registration of pharmacists, operates on the assumption of a physical dispensing environment. In this legislative vacuum, e-pharmacies have functioned by extending the licence of a registered physical pharmacy to their online operations. The platform's registered pharmacy partner technically performs the dispensing, while the digital platform handles the consumer interface and logistics. This arrangement has legal ambiguity — it has been interpreted differently by courts and regulatory authorities in different states. [8] The table below summarises the key legislations and regulatory bodies relevant to e-pharmacies in India:

Table 3: Regulatory Framework Applicable to E-Pharmacies in India

Legislation/Body	Relevance to E-Pharmacies
Drugs & Cosmetics Act, 1940	Primary legislation governing drug manufacture, sale, and distribution. Does not explicitly mention online platforms.
Pharmacy Act, 1948	Regulates pharmacy practice and licensing. Brick-and-mortar focus; not adapted for digital operations.
IT Act, 2000	Applies to digital transactions and data handling by e-pharmacy platforms.
Draft Online Pharmacy Rules, 2018	Proposed mandatory registration, prescription enforcement, and data retention rules. Not yet notified as of 2025.
NDPS Act, 1985	Governs narcotic and psychotropic substances. E-pharmacies explicitly prohibited from selling NDPS-listed drugs.
Personal Data Protection Bill (evolving)	Will govern handling of patient health data collected by platforms — still under parliamentary review.
CDSCO (Regulatory Authority)	Issues alerts on spurious drugs, oversees pharmacovigilance, but lacks specific e-pharmacy enforcement mandate.

The 2018 Draft Rules

The Ministry of Health and Family Welfare released draft rules specifically for online pharmacies in August 2018, proposed as amendments to the Drugs and Cosmetics Rules of 1945. The draft framework proposed that all e-pharmacies must register with a Central Government portal; maintain patient data for a minimum of three years; only accept prescriptions issued by a registered medical practitioner; restrict sales of Schedule H, H1, and X drugs to verified prescription holders; and prohibit the online sale of NDPS Act drugs entirely. [9] The draft received strong opposition from the All-India Organisation of Chemists and Druggists (AIOCD), which argued that e-pharmacies posed an existential threat to traditional pharmacies and an unmanageable risk to prescription drug safety. The rules were never notified as final, and as of 2025, the e-pharmacy sector continues to operate without a finalised specific regulatory framework — a situation that is increasingly untenable as the sector scales.

Judicial Interventions

The Madras High Court in 2018 passed an interim order directing a ban on online pharmacy sales in Tamil Nadu, citing concerns about prescription verification and the unchecked sale of habit-forming and psychotropic medicines. The Supreme Court subsequently stayed this order while allowing the case to proceed. Multiple petitions in various High Courts have raised similar concerns, reflecting genuine judicial discomfort with the absence of regulatory clarity. [10]

KEY DRIVERS OF GROWTH

The rise of e-pharmacies in India cannot be attributed to any single factor. Rather, it has been the confluence of several structural, technological, and behavioural forces. Digital infrastructure development has been the foundational enabler. India's mobile internet revolution — driven by Reliance Jio's entry in 2016, which dramatically reduced the cost of data — brought hundreds of millions of new smartphone users online. By 2024, India had over 700 million active smartphone users, with digital payments via UPI processed at a scale of billions of transactions per month. This digital infrastructure made e-commerce in healthcare not just possible but practical for a broad population base. [1] India's chronic disease burden has created a structural demand for reliable, recurring medicine supply. The country has approximately 77 million diabetic patients — the second largest such population in the world — and tens of millions more managing hypertension, thyroid disorders, asthma, and cardiovascular conditions. These patients require monthly prescription fulfilment, making them ideally suited to the subscription and auto-refill models that e-pharmacies have developed. [11] Price sensitivity among Indian medicine consumers is another critical driver. E-pharmacies consistently offer discounts of 10–25% on MRP, generic alternatives at significantly lower price points, and cashback incentives through digital payment platforms. For a middle-class family spending INR 3,000–6,000 per month on medicines for chronic conditions, these savings are meaningful. The availability of generics — which many traditional pharmacists either do not stock or actively discourage in favour of branded equivalents — has been a particular draw. The COVID-19 pandemic, as discussed earlier, acted as a behaviour-change catalyst of unprecedented scale, driving a generation of first-time online pharmacy users who, in a significant proportion, have continued using the channel post-pandemic. [5] Finally, teleconsultation integration has created a seamless digital health journey — from symptom to consultation to prescription to medicine delivery — that physical systems cannot replicate. This end-to-end convenience is a powerful retention driver, particularly for urban, digitally literate consumers.

CHALLENGES AND CONCERNS

1. Prescription Verification Integrity

The most serious and widely documented concern about e-pharmacies in India is the inconsistency with which prescription requirements are enforced. Schedule H drugs — which include antibiotics, antidepressants, antihypertensives, and several other critical medicines — legally require a valid prescription issued by a registered medical practitioner. Schedule H1 drugs, which carry a higher risk of misuse, have even stricter requirements. Multiple investigative reports and academic studies have found that several e-pharmacy platforms either do not require prescriptions for Schedule H medicines, accept prescriptions without meaningful verification (a photograph is accepted without authenticating whether the prescribing doctor is registered or whether the prescription is genuine), or allow users to repeatedly purchase the same prescription quantity beyond what the prescription period should permit. [12] This creates a pathway for self-medication with prescription-only drugs — a significant antibiotic resistance risk, among other public health concerns.

2. Risk of Counterfeit and Substandard Medicines

The marketplace model, while commercially efficient, introduces a quality assurance vulnerability. When a platform aggregates inventory from hundreds of partner pharmacies, it has limited direct control over the storage conditions, source documentation, and expiry management at each partner outlet. CDSCO has raised alerts about substandard and spurious drugs being sold through online channels, and the absence of a track-and-trace system for online pharmaceutical transactions makes enforcement difficult. [13]

3. Data Privacy and Security

E-pharmacies are repositories of extremely sensitive personal health information — prescription histories, diagnostic reports, chronic disease profiles, doctor–patient communication records, and financial transaction data. India's regulatory framework for health data protection is still evolving. The Digital Personal Data Protection Act, 2023, establishes broad principles for data processing but sector-specific norms for health data remain undefined. Platform data breaches or the unauthorised sale of aggregated patient data to insurance companies, pharmaceutical marketers, or research firms represent real and largely unaddressed risks. [14]

4. Cold Chain and Delivery Reliability

A significant category of medicines — including insulin, certain biologics, vaccines, and several oncology drugs — require continuous cold chain storage at temperatures between 2°C and 8°C. Maintaining an unbroken cold chain from warehouse to patient doorstep is technically demanding and expensive, particularly for deliveries to remote or semi-urban locations. While major platforms have invested in cold chain infrastructure for metro and tier-1 deliveries, reliability in smaller towns and villages remains inconsistent. For patients dependent on insulin, a cold chain failure is not merely an inconvenience — it can render medication ineffective. [7]

5. Impact on Traditional Pharmacists and the Chemist Community

The AIOCD and state-level chemist associations have been among the most vocal opponents of e-pharmacy expansion. Their concerns are partly economic — discounted pricing and the convenience of home delivery draw customers away from local chemists — and partly professional. Traditional pharmacists argue that the face-to-face dispensing interaction allows them to identify dose errors, screen for drug interactions, and provide patient counselling in ways that a digital transaction cannot replicate. The livelihoods of approximately 1.2 million pharmacy workers employed in retail pharmacies are directly linked to the health of this sector. [3]

6. Digital Divide and Equity Concerns

While e-pharmacies promise democratised medicine access, the reality is more nuanced. The poorest and most remote segments of India's population — those arguably most in need of improved medicine access — are also the least likely to have reliable smartphone access, stable internet connectivity, digital literacy, or the ability to navigate complex app interfaces. Delivery timelines to remote rural areas often stretch to 5–7 days, which is unsuitable for urgent medicine needs. Cash-on-delivery options exist, but the digital payment ecosystem that makes e-pharmacy convenient is not uniformly accessible.

ILLUSTRATIVE CASE EXAMPLES

Case 1: PharmEasy — Hyper-Growth and Financial Recalibration

PharmEasy's trajectory represents both the extraordinary opportunity and the financial risks in this sector. The platform grew from a Mumbai-based startup in 2014 to a valuation of over USD 5.6 billion within seven years — one of the fastest-growing health-tech companies in Indian history. It aggressively expanded into diagnostics through the acquisition of Thyrocare for approximately USD 612 million in 2021. However, the anticipated IPO, which would have been one of the largest in India's health-tech history, was withdrawn in 2022 as market conditions deteriorated and profitability timelines extended. The company subsequently raised capital through a rights issue at a valuation of approximately USD 300 million — a fraction of its earlier peak — illustrating that high-growth narratives in e-pharmacy do not automatically translate into sustainable financial models. [6]

Case 2: 1mg Under Tata — Brand Trust and Ecosystem Integration

Tata Digital's acquisition of 1mg transformed the platform's positioning fundamentally. The Tata brand association addressed a key consumer hesitation — can I trust this online platform with my health and my data? Post-acquisition, 1mg has invested in prescription verification technology, expanded its private label generics range under the '1mg Generics' brand, and integrated with Tata's broader health and wellness ecosystem including insurance products through Tata AIG and digital health records. The integration approach reflects a mature understanding that sustainable e-pharmacy growth requires trust as much as convenience. [4]

Case 3: Apollo Pharmacy — The Phygital Advantage

Apollo Hospitals' entry into online pharmacy has been built on the strength of its existing physical pharmacy network. With over 4,000 Apollo Pharmacy outlets across India and a reputation built over decades in healthcare, the platform has a structural advantage that pure-play digital entrants cannot easily replicate. Its hybrid model — where online orders can be fulfilled from the nearest Apollo store, and customers can also choose in-store pickup — addresses the cold chain, prescription verification, and trust concerns that digital-only models struggle with. Apollo's approach demonstrates that the future of pharmacy retail in India may increasingly be 'phygital' rather than purely digital.

FUTURE OUTLOOK

The Indian e-pharmacy sector stands at a point of significant opportunity and equally significant regulatory responsibility. Several trends will shape its trajectory over the next five to ten years.

Regulatory clarity, when it arrives, will be the single most consequential development. The notification of finalised online pharmacy rules — including robust prescription authentication requirements, mandatory platform registration, and clear data protection standards — will define the boundaries within which legitimate platforms can operate and the consequences for non-compliance. Integration with the Ayushman Bharat Digital Mission (ABDM) and the linking of prescriptions to ABHA (Ayushman Bharat Health Account) IDs could enable a digital verification system that is both robust and patient-friendly. [15] Artificial intelligence is beginning to play a meaningful role in prescription analysis, drug interaction checking, and personalised health recommendations. Several platforms are piloting AI-assisted pharmacist review systems that flag potential prescription issues before dispensing. While AI cannot replace the clinical judgement of a trained pharmacist, it can augment quality control at scale in ways that human review alone cannot achieve for high-volume digital operations. The integration of teleconsultation, diagnostics, and medicine delivery into a seamless 'health journey' — what the industry terms the 'digital health super-app' — is a direction several major platforms are pursuing. For patients managing chronic conditions, the ability to consult a doctor, receive a digital prescription, book a home blood test, and have medicines delivered through a single platform represents a genuinely valuable convenience. Executed responsibly, this model could significantly improve health outcomes and medication adherence across India's chronic disease population. [11] Finally, government-led initiatives such as Jan Aushadhi Kendras — which distribute quality generics at government-controlled prices through physical outlets — may increasingly develop a digital interface, creating a public sector e-pharmacy channel that competes on affordability. The interaction between private e-pharmacy platforms and government health distribution systems will be an important dynamic to watch.

CONCLUSION

The rise of e-pharmacies in India represents one of the most consequential transformations in the country's healthcare delivery system in recent decades. Beginning as a modest experiment in digital health commerce, the sector has matured into a sophisticated, multi-billion-dollar industry that has demonstrably expanded medicine access, improved pricing transparency, and enabled new care pathways for millions of patients — particularly those managing chronic conditions in geographically underserved areas. The growth story, however, is incomplete and in some respects troubling. The sector's most critical vulnerability — the inconsistent enforcement of prescription requirements — is not a minor operational detail. It is a patient safety issue with real-world consequences: potential antibiotic misuse, self-medication with potent prescription drugs, and the erosion of the pharmacist's essential clinical role. These concerns cannot be set aside in the enthusiasm for a compelling technology narrative. India needs e-pharmacies. The structural gaps in its traditional pharmacy system are real, and digital platforms offer genuine solutions to real problems. But India also needs e-pharmacies that are accountable, regulated, and operating within a framework that protects patients as rigorously as it serves them. The finalization of the Online Pharmacy Rules, integration with the ABDM digital health infrastructure, meaningful investment in pharmacist training and oversight at the platform level, and transparent data governance are not optional additions to this sector's future — they are prerequisites for it to earn the trust that sustainable growth requires. The e-pharmacy story in India is still being written. Whether it becomes a chapter about responsible innovation improving public health at scale, or a cautionary tale about what happens when commercial momentum outpaces regulatory oversight, will depend significantly on the decisions made by policymakers, platform operators, and the pharmacy profession in the years ahead.

CONFLICT OF INTEREST

The authors have no conflicts of interest.

REFERENCES

India Brand Equity Foundation (IBEF). Pharmaceuticals Industry in India: Sector Overview and Market Analysis. Ministry of Commerce & Industry, Government of India; 2024. Available from: https://www.ibef.org/industry/pharmaceutical-india [1]
All India Organisation of Chemists and Druggists (AIOCD). White Paper on Online Pharmacy Regulation: Concerns and Recommendations. New Delhi: AIOCD; 2019. [2]
Srinivasan S, Phadke A. Generic Medicines and Irrational Drug Use in India: Challenges in Retail Pharmacy. Indian J Med Ethics. 2020;5(2):89–96. [3]
Tata Digital Limited. Annual Report and 1mg Integration Update. Mumbai: Tata Digital; 2022–23. Available from: https://www.tata.com [4]
Kalra S, Kalra B. COVID-19 and the Rise of Digital Health in India. Diabetes Ther. 2020;11(8):1675–1678. https://doi.org/10.1007/s13300-020-00872-y [5]
API Holdings Limited. Red Herring Prospectus — Withdrawn. Mumbai: SEBI Filing; 2021. Available from: https://www.sebi.gov.in [6]
Vaidya V, Bhatt P. Cold Chain Logistics for Pharmaceuticals in India: Infrastructure Gaps and Policy Needs. J Pharm Policy Pract. 2021;14(1):62. https://doi.org/10.1186/s40545-021-00350-3 [7]
Ministry of Health and Family Welfare. Drugs and Cosmetics Act, 1940 (as amended). Government of India. Available from: https://cdsco.gov.in [8]
Ministry of Health and Family Welfare. Draft Rules for Online Pharmacies — Amendment to Drugs and Cosmetics Rules, 1945. Gazette of India, Extraordinary; August 2018. [9]
Madras High Court. Tamil Nadu & Ors vs. Union of India & Ors. W.P. No. 28716 of 2018. High Court of Judicature at Madras; 2018. [10]
International Diabetes Federation. IDF Diabetes Atlas, 10th Edition. Brussels: IDF; 2021. Available from: https://diabetesatlas.org [11]
Garg S, Wouters OJ. Regulation of Online Pharmacies in Low- and Middle-Income Countries: Evidence and Recommendations. BMJ Glob Health. 2022;7(4):e007912. https://doi.org/10.1136/bmjgh-2021-007912 [12]
Central Drugs Standard Control Organisation (CDSCO). Public Alert on Spurious Medicines Available Through Online Channels. New Delhi: CDSCO; 2022. Available from: https://cdsco.gov.in [13]
Ministry of Electronics and Information Technology. Digital Personal Data Protection Act, 2023. Government of India; 2023. Available from: https://meity.gov.in [14]
National Health Authority. Ayushman Bharat Digital Mission: Framework and Implementation Plan. Government of India; 2022. Available from: https://abdm.gov.in [15]